2026-06-14T11:55:09Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/201122024-11-28T20:14:20Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud
author
Gutierrez, Antonio
author
Bento, Leyre
author
Maria Bautista-Gili, Antonia
author
Garcia, Francesc
author
Martinez-Serra, Jordi
author
Sanchez, Blanca
author
Martorell, Clara
author
Gines, Jordi
author
Garcia, Lucia
author
Gimeno, Eva
author
Ferraro, Mariana
author
del Campo Garcia, Raquel
author
Bargay Lleonart, Joan
author
Perez, Albert
author
Vercher, Javier
author
Scaff, Miguel
author
Pacheco, Ana
author
Ballester Ruiz, Maria del Carmen
author
Garcia, Florencia
author
Ramos-Asensio, Rafael
author
Salar, Antonio
author
Besalduch Vidal, Juan
2024-07-04T12:54:58Z
2024-07-04T12:54:58Z
2015-04-24
Gutierrez A, Bento L, Bautista-Gili AM, Garcia F, Martinez Serra JJ, Sanchez B, et al. Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14. PLoS One. 2015 Apr 24;10(4):e0123978.
10.1371/journal.pone.0123978
1932-6203
PloS One
http://hdl.handle.net/20.500.13003/10877
25909361
L604108257
2-s2.0-84929483958
http://hdl.handle.net/20.500.12105/20112
353376800053
DLBCL is an aggressive lymphoma treated with R-CHOP. Recently, attempts have been made to improve the outcome by increasing both dose-density and intensity but there have been no benefits in terms of survival. When treating malignancies RDI is important to consider but there is little published information on DLBCL. The purpose of this study was to analyze the differential prognostic impact of RDI in two cohorts of DLBCL patients treated with R-CHOP21 or R-CHOP14. From January 2001 to August 2013 we included DLBCL patients homogenously treated with R-CHOP21 or R-CHOP14, with or without radiotherapy, at University Hospital Son Espases, Hospital Son Llatzer of Palma and Hospital del Mar of Barcelona (N = 157). In order to avoid selection bias the patients were retrospectively identified from the Pathology Department and Pharmacy registries. Median follow-up was 68 months. There was no difference in the response or survival between the two cohorts. In the R-CHOP21 group, both a reduction higher than 15% in RDI (RR 7.41) and R-IPI (RR 2.99) were independently associated with OS. However, a reduction higher than 15% in RDI (RR 4.41) was only noted for PFS. In the R-CHOP14 group, NCCN-IPI (RR 7.09) and B-symptoms (RR 5.37) for OS; AA stage III-IV (RR 6.26) and bulky disease (RR 4.05) for PFS. There was a trend towards a higher rate of RDI reduction observed in the R-CHOP14 group but it only made an impact in the R-CHOP21 group. We conclude that R-CHOP21 and R-CHOP14 are equivalent regimens in terms of response and survival, but only if RDI reductions are avoided. For patients receiving R-CHOP21 we recommend using clinical and support measures in order to avoid RDI reductions.
eng
Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14
research article